GlassScriptPhysician profile
Shiraz A Khaiser
NPI 1568681740
$3,767.59
in general payments reported to CMS, 2019-2025
20 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $281 · 2021: $692 · 2022: $1,051 · 2023: $395 · 2024: $475 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,939.22 | 2019-2025 | |
| Janssen Biotech, INC. | $409.37 | 2020-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $268.13 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.46 | 2019-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $141.73 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $131.70 | 2025 | Rezdiffra |
| Ethicon US, LLC | $128.50 | 2019 | |
| Celgene Corporation | $125.30 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $117.64 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $109.05 | 2019 | |
| Pfizer INC. | $51.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.72 | 2022 | |
| Braintree Laboratories, INC. | $30.19 | 2021-2022 | |
| Ucb, INC. | $28.90 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $17.15 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $16.90 | 2021 | |
| Alfasigma USA, INC. | $12.00 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.05 | 2020 | |
| Organon LLC | $9.33 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,987.16 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiraz Khaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.